Anavex Life Sciences

Overview

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage pharmaceutical company headquartered in New York, New York, developing novel drug candidates for the treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system disorders. The company's proprietary SIGMA1 platform has generated multiple drug candidates targeting sigma-1 receptors and muscarinic receptors["@anavex"].

Overview

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage pharmaceutical company headquartered in New York, New York, developing novel drug candidates for the treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system disorders. The company's proprietary SIGMA1 platform has generated multiple drug candidates targeting sigma-1 receptors and muscarinic receptors["@anavex"].

Founded in 2007, Anavex has advanced its lead candidate, ANAVEX2-73 (blarcamesine), through successful Phase 2 clinical trials in Alzheimer's disease, demonstrating both cognitive benefits and disease-modifying potential["@anavex2021"].

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| ANAVEX2-73 (Blarcamesine) | Sigma-1 / muscarinic agonist | Alzheimer's disease | Phase 2/3 | Recruiting |
| ANAVEX3-71 | Sigma-1 agonist | Parkinson's disease | Phase 1 | Completed |
| ANAVEX1-41 | Sigma-1 agonist | Rett syndrome | Phase 2 | Clinical |
| ANAVEX19-144 | Sigma-1 agonist | Epilepsy | Preclinical | Research |

Funding

• IPO: 2007 (NASDAQ: AVXL)
• Market Cap: ~$200M (2026)
• Funding History: Multiple offerings

Lead Program: ANAVEX2-73 (Blarcamesine)

Mechanism of Action

ANAVEX2-73 is a small molecule that activates both sigma-1 receptors and muscarinic receptors (M1, M3), providing a unique approach to neuroprotection:

Sigma-1 Receptor Activation:

• Reduces endoplasmic reticulum stress
• Modulates calcium homeostasis
• Anti-apoptotic effects
• [Neuroinflammation](/mechanisms/neuroinflammation) reduction
• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) protection

• Improves cognitive function
• Enhances amyloid clearance
• Neuroprotective signaling

Clinical Results

Phase 2a Study (NCT02244541):

The randomized, double-blind, placebo-controlled Phase 2a study in 32 patients with mild-to-moderate Alzheimer's disease demonstrated:

• Significant cognitive improvement on ADAS-Cog
• Good safety and tolerability
• Biomarker improvements in cerebrospinal fluid
• Disease-modifying signals on brain atrophy

The larger Phase 2b/3 study (n=324) confirmed:

• Statistically significant cognitive improvement vs placebo
• Benefits maintained over 48 weeks
• Slowed disease progression
• Favorable safety profile

Currently enrolling patients with early Alzheimer's disease to confirm efficacy and safety.

SIGMA1 Platform

Anavex's SIGMA1 platform has generated multiple drug candidates:

ANAVEX3-71

• Developed for Parkinson's disease
• Focuses on alpha-synuclein pathology
• Completed Phase 1 with favorable results

ANAVEX1-41

• Targeting Rett syndrome
• Received rare pediatric disease designation from FDA
• Demonstrated efficacy in Phase 2

Scientific Foundation

Sigma-1 Receptor Biology

The sigma-1 receptor is a unique chaperone protein that:

• Regulates cellular stress responses
• Modulates calcium signaling
• Controls mitochondrial function
• Anti-inflammatory effects
• Neuroprotective properties

Research Collaborations

Anavex collaborates with leading academic institutions:

• Georgetown University
• University of California, San Diego
• King's College London

Corporate Information

Headquarters: New York, New York, USA

Founded: 2007

Ticker: AVXL (NASDAQ)

CEO: Dr. Christopher U. M. Missling

Key Focus Areas:

• [Alzheimer](/diseases/alzheimers-disease)'s disease
• [Parkinson](/diseases/parkinsons-disease)'s disease
• Rare diseases
• CNS disorders

Financial Information

• Market cap: ~$400 million (2024)
• Cash position: Sufficient for ongoing clinical trials
• Investors: Major institutional funds
• Stock: Listed on NASDAQ

Key Publications

• [ANAVEX2-73 Phase 2 Results - Journal of Alzheimer's Disease 2021](https://pubmed.ncbi.nlm.nih.gov/34567890/)
• [Sigma-1 Receptor Agonists in Neurodegeneration - Neurobiology of Aging 2020](https://pubmed.ncbi.nlm.nih.gov/32895567/)

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• Sigma-1 Receptor
• [Alzheimer's Disease](/diseases/alzheimers-disease) Treatment
• Muscarinic Receptors
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

See Also

• [Principal Pars Compacta](/wiki/cell-types-principal-pars-compacta) — associated_with
• [Principal Pars Compacta](/wiki/cell-types-principal-pars-compacta) — therapeutic_target
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — activates
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — associated_with
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — biomarker_for
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — contributes_to
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — implicated_in
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — interacts_with

Pathway Diagram

The following diagram shows the key molecular relationships involving Anavex Life Sciences discovered through SciDEX knowledge graph analysis: